Chromosomal Instability in Ovarian Cancer

Study Overview
=================
Brief Summary
-----------------
Chromosomal instability (CIN) refers to the ongoing genomic change, which involves the amplification or deletion of chromosome copy number or structure. The changes rang from point mutation to small-scale genomic change and even the change of whole chromosome number. It has been reported that the characteristics of genomic rearrangement can be used as a marker of clinical outcome of high-grade serous ovarian cancer, and specific genomic rearrangement are related to the poor prognosis. In noninvasive gene detection with low coverage, patients diagnosed with ovarian cancer have deteriorating progression-free and overall survivals regardless of the tumor stage when somatic copy number distortion (sCNA) exceeds the threshold in plasma. The detection rate of sCNA increased along with the tumor stage. We enrolled those as our target patients, who are diagnosed with high-grade serous ovarian cancer and willing to take part in. The CIN in peripheral cell-free DNA was observed before initial treatment, after primary debulking or staging surgeries, before recurrence and during the process of recurrence treatment. Our aim is to explore the application of CIN in peripheral tumor DNA in the detection of minimal residual lesions (MRD) after primary treatment and recurrence monitoring.

Official Title
-----------------
The Role of Chromosomal Instability in Monitoring the Course of Ovarian High-grade Serous Carcinoma

Conditions
-----------------
Epithelial Ovarian Cancer, High-grade Serous Ovarian Carcinoma, Chromosomal Instability, Somatic Copy Number Distortion, Survival Outcomes, Minimal Residual Lesions, Progression-free Survival, Overall Survival

Intervention / Treatment
-----------------
* Diagnostic Test: Testing for chromosomal instability (CIN)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed of primary ovarian high grade serous carcinoma (HGSC) Aged 18 years or older Acceptance of surgical treatment for HGSC With detailed follow-up outcomes Exclusion Criteria: Not meeting all of the inclusion criteria Declining to anticipate the trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Testing for chromosomal instability (CIN)|The CIN in peripheral cell-free DNA was observed before initial treatment, after primary debulking or staging surgeries, before recurrence and during the process of recurrence treatment.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of chromosomal instability (CIN) | Incidence of chromosomal instability tested in peripheral cell-free DNA | One year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival | Progression-free survival in patients accepting CIN testing | One year | 
| Overall survival | Overall survival in patients accepting CIN testing | One year |